Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Vascular hypertrophy suppression treatment|
|Abstract:||This invention relates to a method for the prophylaxis or treatment of vascular hypertropy in a mammal by administering a pharmaceutically effective amount of a compound represented by the formula (I): ##STR1## wherein ring W is a nitrogen-containing heterocyclic ring residue which may be substituted; R.sup.1 is hydrogen or an optionally substituted hydrocarbon residue which optionally binds through a hetero-atom; R.sup.3 represents a group capable of forming an anion or a group capable of changing thereto; X shows that the phenylene and phenyl groups bind to each other directly or through a spacer having an atomic length of two or less; n denotes 1 or 2; a and b forming the heterocyclic ring residue are independently one or two optionally substituted carbon or hetero atoms; c is an optionally substituted carbon or hetero atom; provided that, when the ring W is a condensed ring, R.sup.1 is hydrogen or an optionally substituted hydrocarbon residue which binds through a hetero atom, or a salt thereof to a mammal in need thereof.|
|Inventor(s):||Nishikawa; Kohei (Kyoto, JP)|
|Assignee:||Takeda Chemical Industries, Ltd. (Osaka, JP)|
Patent Claim Types:|
see list of patent claims
|Patent Number||Expiration Date|
|5,508,297||April 16, 2004|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Japan||5-036630||Feb 25, 1993|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.